A Phase 2 Randomized Open-Label Study of Oral ODM-201 vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer

Trial Profile

A Phase 2 Randomized Open-Label Study of Oral ODM-201 vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Darolutamide (Primary) ; Degarelix; Goserelin; Leuprorelin; Triptorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Nov 2016 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
    • 28 Nov 2016 Planned primary completion date changed from 1 Feb 2020 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top